Skip to main content
Medical Reference · Condition Monograph

Neuromyelitis Optica Spectrum Disorder

시신경척수염

Neuromyelitis optica spectrum disorder is a group of autoimmune diseases in which acute inflammation recurs in the optic nerves and spinal cord and can leave serious sequelae such as loss of vision and paralysis.

History

Neuromyelitis optica spectrum disorder is a group of autoimmune diseases in which acute inflammation recurs in the optic nerves and spinal cord and can leave serious sequelae such as loss of vision and paralysis. In the past, it was long treated as a variant of multiple sclerosis, because both diseases cause optic neuritis and myelitis and can sometimes look similar on imaging. However, as it was reported that the clinical course is more abrupt, that the disability left by a single attack is greater, and that multiple sclerosis drugs can actually make it worse, suspicion grew that "it may be a different disease."

The decisive turning point was the discovery of the disease's "target," the anti-aquaporin-4 antibody. As evidence accumulated that the group of patients positive for this antibody shows distinct clinical features and pathological findings and also responds differently to treatment, the disease's independence was established. Later, with the discovery of the anti-myelin oligodendrocyte glycoprotein antibody, it also became clear that some antibody-negative patients actually belong to a different disease group. Today, therefore, the approach has become established of distinguishing different diseases according to antibody status and organizing, under the name "spectrum," groups that are clinically similar but differ in cause.

The diagnostic criteria have also changed. The 2015 international consensus criteria emphasized early diagnosis by allowing the diagnosis with relatively little clinical evidence in anti-aquaporin-4 antibody-positive cases, while requiring stricter clinical and imaging conditions when the antibody is absent or its status unknown, in order to reduce misdiagnosis. The history of treatment has also changed greatly: targeted biologic agents such as complement inhibition, B cell-targeted therapy, and interleukin-6 pathway inhibition have emerged, refining relapse prevention strategies.

Causes

The direct cause of this disease is that the immune system mistakenly recognizes specific proteins of the optic nerves and spinal cord (and sometimes the brainstem, hypothalamus, and other areas) as an "enemy" and attacks them. The main criterion for dividing patient groups is which antibody is involved. In many patients the anti-aquaporin-4 antibody is found, and in some the anti-myelin oligodendrocyte glycoprotein antibody is found. There are also cases in which neither antibody is present; in these cases the cause may not be a single one, and several diseases may be mixed together, so more careful differentiation is needed.

In anti-aquaporin-4 antibody-positive disease, the supporting cells of the brain called "astrocytes" are the target. In other words, rather than a disease that attacks only myelin, it is understood as a form in which astrocytes are damaged first and, as a result, myelin and nerves are damaged secondarily. In disease involving the anti-myelin oligodendrocyte glycoprotein antibody, the target is closer to the myelin.

Why this autoimmunity begins is not clear. However, because it is much more common in women and sometimes coexists with other autoimmune diseases (e.g., systemic lupus erythematosus, Sjögren syndrome), immune constitution is regarded as an important background. Recent studies have summarized reports that environmental factors such as vitamin D deficiency, certain infections and immune responses, and dietary patterns may be associated with the risk of onset.

Genetic Epidemiology

Neuromyelitis optica spectrum disorder is not a typical hereditary disease, but genetic predisposition can raise the risk. Notably, there are reports that some types of human leukocyte antigen genes are associated with risk. Because this is a group of genes that affects how the immune system recognizes antigens, it is a link that appears repeatedly across autoimmune diseases in general.

Having a family history does not mean the disease will necessarily develop. However, several autoimmune diseases sometimes appear together within the same family, and such cases can be understood as a shared "constitution in which the immune system can become hypersensitive." In other words, rather than a specific gene causing the disease on its own, a model in which multiple genetic and environmental factors overlap to raise the risk is more appropriate.

Recent studies have emphasized the interaction between genetic background and environmental factors to explain why prevalence and patterns of onset differ by race and region. However, genetic testing has not become widely established to the point of directly determining diagnosis or prognosis at the individual level, and in current clinical practice the key elements are antibody testing and clinical and imaging findings.

General Epidemiology

This disease falls into the category of rare diseases, but it is reported relatively more often in certain populations. Overall it shows a very high proportion in women, and there are observations that anti-aquaporin-4 antibody-positive cases often begin in middle age. Differences in frequency by race have also been reported, and some studies conclude that it is more common in non-white populations.

A clinically important epidemiological feature is "relapse." Without treatment, a relapsing course is common, and with each attack vision and limb function can decline greatly. The burden of the disease is therefore determined less by simple prevalence than by "whether relapse can be prevented."

Another change is that changes in the diagnostic system affect epidemiological figures. Since the 2015 diagnostic criteria, as antibody testing has become widely performed, patients who were previously classified as having multiple sclerosis and other conditions have increasingly been reclassified. Recent studies have repeatedly emphasized that misdiagnosis and reclassification can occur when the diagnostic criteria are applied in everyday practice, so standardization of antibody testing methods and image interpretation is important.

Pathogenesis

In anti-aquaporin-4 antibody-positive disease, a chain reaction begins when the antibody enters the brain from the blood and binds to the aquaporin-4 protein on the surface of astrocytes. When the antibody binds, the immune response system called complement is activated, and as a result astrocytes are damaged. Inflammatory cells gather at the damaged sites, and as oxidative stress and inflammatory substances increase, the surrounding nerves and myelin are damaged as well. This process is especially severe in the optic nerves and spinal cord, and the abundance of aquaporin-4 in these structures is presented as a clue explaining the selective involvement.

In anti-myelin oligodendrocyte glycoprotein antibody-associated disease, the target is closer to the cells that make myelin and to myelin surface proteins, so the pattern of tissue damage can differ. Clinically, both can cause optic neuritis and myelitis, but they differ in the degree of recovery, relapse patterns, and imaging features, which influences the choice of treatment.

The route by which antibodies enter the brain has not been fully elucidated, but there are explanations that they may enter through gaps where the blood-brain barrier has weakened, or may first invade brain regions where the barrier is inherently relatively weak (e.g., the region containing the vomiting center). Recent studies have emphasized the view that inflammatory signals such as interleukin-6 can make the blood-brain barrier looser and promote antibody production, worsening the disease.

Symptoms

The representative symptoms are optic neuritis and myelitis. In optic neuritis, vision in one or both eyes drops suddenly, and pain may accompany eye movement. It may also begin as difficulty distinguishing colors or partial obstruction of the visual field. In this disease, optic neuritis relatively often involves severe vision loss from the outset and both eyes at the same time, and recovery is incomplete, so the risk of residual visual impairment is high.

Myelitis can present as weakness or numbness in the arms and legs, dulled sensation, and a sensory level below the waist. Bladder dysfunction, in which urine does not come out easily or, conversely, is difficult to hold, and bowel dysfunction such as constipation may also accompany it. In severe cases, paralysis can progress rapidly, making walking difficult or requiring a wheelchair.

Other characteristic symptoms include persistent unexplained hiccups, nausea, and vomiting. These can be associated with involvement of a specific area of the brainstem (the vomiting center). Brainstem symptoms such as dizziness, difficulty swallowing, abnormal speech, and abnormal eye movements, or symptoms around the hypothalamus such as excessive sleepiness and hormonal abnormalities, may also appear.

Fatigue is also common and can greatly reduce quality of life. Recent studies have concluded that problems such as depression and cognitive decline may be underdiagnosed just as much as visual and motor impairments. Because the symptoms are diverse, it is important to keep the possibility of this disease in mind even when it presents in an atypical form.

Signs

The signs that the medical team confirms are objective findings of reduced optic nerve function and spinal cord dysfunction. On vision testing, visual acuity is reduced and color vision is impaired, and optic disc swelling may be seen on fundus examination. Defects may also be confirmed on visual field testing. In myelitis, muscle weakness, changes in reflexes, a sensory level, changes in muscle tone, and gait abnormalities may be confirmed.

One of the characteristics of this disease is that the disability left by a single attack is large. Even after an attack, vision or limb function often does not recover completely, and residual disability remains. In addition, recurrent myelitis can lead to spinal cord atrophy.

On imaging, spinal cord lesions extending over a long segment can be a clue, and optic nerve lesions that involve a long segment or include the optic chiasm are also noteworthy. However, because these findings are not always present, antibody testing and the clinical picture must be considered together.

Screening

The goal of screening is not to miss "warning signs that require distinction from multiple sclerosis." When vision loss is severe, optic neuritis occurs in both eyes at the same time, myelitis symptoms are extensive and progress rapidly, or hiccups and vomiting persist for several days or more, this disease should be suspected first at the screening stage.

In the emergency department or outpatient clinic, the history and neurological examination are taken first, and the optic nerves and spinal cord are quickly evaluated with magnetic resonance imaging. At the same time, antibody tests (anti-aquaporin-4 antibody, anti-myelin oligodendrocyte glycoprotein antibody) are performed on the blood to obtain clues for classification.

An important point in the screening process is not to start multiple sclerosis drugs hastily. This is because some multiple sclerosis drugs can cause worsening in this disease. Recent studies have emphasized that the choice of antibody testing method (especially cell-based assays) and the timing of testing are important in reducing misdiagnosis.

Diagnosis

The diagnosis is made by combining clinical symptoms, antibody testing, and imaging findings. The 2015 consensus criteria are designed to be relatively simple, so that in anti-aquaporin-4 antibody-positive cases the diagnosis is possible with only one core clinical characteristic (e.g., optic neuritis, myelitis, area postrema syndrome with vomiting and hiccups, and others) once alternative diagnoses are excluded. Conversely, when the antibody is negative or its status unknown, two or more different core clinical characteristics are needed, and imaging conditions supporting each of them are required.

The key tests are blood antibody testing and magnetic resonance imaging. Lesions extending over a long segment in the spinal cord, and long-segment involvement or involvement of the optic chiasm in the optic nerves, can be clues. Cerebrospinal fluid testing helps differentiate it from other diseases, and the fact that oligoclonal bands, which are common in multiple sclerosis, may be rare or transient in this disease is mentioned as a point of differentiation.

Differential diagnosis is very important. Multiple sclerosis, anti-myelin oligodendrocyte glycoprotein antibody-associated disease, infectious myelitis, vascular myelopathy, and nervous system involvement accompanying systemic autoimmune diseases are among the conditions to be differentiated. Recent studies have presented the view that because the antibody-negative patient group may be heterogeneous, it should not simply be lumped together but needs reevaluation.

Treatment

Treatment is divided into acute treatment and relapse prevention treatment. In the acute phase, high-dose intravenous corticosteroids are used as first-line treatment, and if the response is insufficient or the attack is severe, plasma exchange can be performed promptly. The key to acute treatment is "time." Because tissue damage continues while an attack is in progress, the inflammation must be stopped as soon as possible to reduce sequelae.

Relapse prevention is the center of long-term treatment. In the past, immunosuppressants such as azathioprine or mycophenolate, or B cell-targeted therapy such as rituximab, have been widely used. Recently, it has been reported that in anti-aquaporin-4 antibody-positive patients, targeted biologic agents such as complement inhibitors, B cell-lineage targeted therapy, and interleukin-6 pathway inhibitors can greatly reduce relapses.

The choice of treatment depends on antibody status, past relapse frequency, coexisting autoimmune diseases, infection risk, and cost and accessibility. Vaccination is also important. In particular, when complement inhibitors are used, the risk of certain infections can increase, so vaccination and infection surveillance are necessary. Because stopping treatment on your own can increase the risk of relapse, any decision should be made in consultation with a specialist.

Prognosis

Regarding prognosis, the most important point is that, unlike multiple sclerosis, the disability left by "a single attack" is large. Loss of vision and paralysis can remain permanently, and repeated attacks create cumulative disability. On the other hand, a form that progresses gradually between attacks is known to be typically not prominent. Relapse prevention treatment therefore determines the prognosis.

The anti-aquaporin-4 antibody-positive group may have a high risk of relapse and accumulation of disability, while anti-myelin oligodendrocyte glycoprotein antibody-associated disease often recovers better, although relapse patterns vary greatly between individuals. When neither antibody is present, the group may be heterogeneous, making prognosis harder to predict.

Recent studies have discussed that, with early diagnosis and the introduction of targeted treatments, relapses are more likely to decrease and the prognosis to improve, but that practical issues such as disparities in access to treatment, infection risk, vaccine response, and the risk of relapse related to pregnancy and childbirth must also be considered. Ongoing specialist care and follow-up have a decisive influence on the long-term prognosis.

Prevention

There is not yet a method of primary prevention, that is, of reliably preventing onset itself. However, "secondary prevention," which manages modifiable risk factors and reduces relapse and sequelae after onset, is very important. Recent studies have concluded that environmental factors such as vitamin D deficiency, exposure to certain infections, and dietary patterns may be associated with risk. However, this is not at a level where it can be asserted that an individual can prevent onset by controlling these alone, and it is more appropriate to understand it in terms of stabilizing immune and metabolic status through healthy lifestyle habits.

The key to secondary prevention is early diagnosis and relapse prevention treatment. Evaluating promptly when vision loss or myelitis symptoms appear, and checking antibody status to start the appropriate preventive treatment, reduces sequelae. In addition, infection prevention, vaccination, and infection surveillance during treatment are important. This is because, in people receiving corticosteroid or immunosuppressive treatment, infections can trigger relapses or complicate treatment.

Education about signs of relapse is also part of prevention. If vision becomes blurred, sensation or strength in the arms and legs changes suddenly, or unexplained hiccups and vomiting persist, evaluation should be sought without delay. The earlier the response, the more permanent nerve damage can be minimized.

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.